Compass Therapeutics, Inc. (CMPX)
(Real Time Quote from BATS)
$1.01 USD
+0.11 (12.22%)
Updated Aug 8, 2024 09:50 AM ET
3-Hold of 5 3
B Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CMPX 1.01 +0.11(12.22%)
Will CMPX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CMPX
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Buy Rating Affirmed on Compass Therapeutics as Clinical Trials of CTX-009 Show Promise in Biliary Tract Cancer Treatment
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Compass Therapeutics completes patient enrollment in COMPANION-002
Compass Therapeutics: Pointing Right At Some Tough Cancers